Welcome to our dedicated page for CASTLE BIOSCIENCES SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CASTLE BIOSCIENCES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CASTLE BIOSCIENCES's regulatory disclosures and financial reporting.
Castle Biosciences president and CEO Derek J. Maetzold reported several equity compensation transactions in company stock. On March 3, 2026, he received a grant of 102,597 Restricted Stock Units (RSUs), which, according to a footnote, vest in four equal annual installments beginning on March 3, 2027.
On March 4, 2026, RSUs previously granted were converted into a total of 59,097 shares of common stock through derivative exercises. On March 3 and March 4, 2026, a combined 36,974 shares of common stock were disposed of at prices of $27.57 and $28.17 per share to satisfy tax withholding obligations.
The filing also lists indirect holdings of common stock in multiple trusts, including The Maetzold Descendants 2020 Trust and several Maetzold remainder and grantor retained annuity trusts, where Maetzold or his spouse serves as trustee and certain family members are beneficiaries.
Castle Biosciences Chief Financial Officer Frank Stokes reported a mix of stock awards, option exercises, sales, and tax-related share withholdings. On March 3, 2026, he was granted 48,367 Restricted Stock Units (RSUs), each representing one share of common stock, vesting in four equal annual installments beginning March 3, 2027.
That same day, he sold 5,300 and 1,700 shares of common stock at weighted-average prices of $27.32 and $27.81 in open-market transactions under a Rule 10b5‑1 trading plan. He also disposed of 3,611 shares at $27.57 to cover tax withholding on previously vested performance stock units.
On March 4, 2026, Stokes exercised derivative awards, converting 12,186 and 11,960 RSUs and 3,800 fully vested stock options into common stock, including 3,800 shares at an exercise price of $3.38. After these transactions, he directly owned 66,086 common shares, including 1,033 shares acquired under the employee stock purchase plan.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting proposed sales of Common shares for Franklin M. Stokes.
The notice lists a sale of 7,000 Common shares on 03/03/2026 for $192,045.00 and a sale of 4,496 Common shares on 12/11/2025 for $168,375.20. The filing references Restricted Stock Units dated 12/09/2023.
CSTL submitted a Form 144 notice reporting a proposed sale of 4,748 common shares via a stock option exercise dated 03/05/2026.
Broker/dealer listed is Morgan Stanley Smith Barney LLC. The filing also lists previously issued restricted stock quantities of 830 (06/10/2022) and 1,825 (06/02/2023).
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 reporting an intended sale of 7,000 common shares originally issued as Restricted Stock Units on 12/09/2023. The filing lists a prior sale of 4,496 common shares on 12/11/2025 for $168,375.20.
The filing identifies the securities as common stock of CSTL and provides broker details and a filing date of 03/03/2026 in the header. This is a routine notice of an affiliate sale under resale reporting rules.
Castle Biosciences, Inc. files its annual report describing its 2025 operations, growth, risks and regulatory environment as a molecular diagnostics company focused on dermatology, gastroenterology, ophthalmology and atopic dermatitis.
In 2025, Castle generated $344.2 million in net revenues and delivered 105,053 clinical test reports, up from 96,071 in 2024. Dermatologic tests accounted for 60,665 reports, while TissueCypher Barrett’s esophagus testing rose sharply to 39,014 reports. The company commenced a limited launch of its non-invasive AdvanceAD‑Tx test for moderate‑to‑severe atopic dermatitis.
The report details broad Medicare and commercial coverage for key tests such as DecisionDx‑Melanoma, TissueCypher, MyPath Melanoma, DecisionDx‑UM and (until discontinued) IDgenetix, with specific ADLT-based Medicare rates. It also explains that DecisionDx‑SCC is now non‑covered under finalized Medicare LCDs, which Castle is seeking to reconsider. Extensive risk disclosures emphasize dependence on a small number of third‑party payors, historical losses, evolving FDA and LDT regulation, intellectual property protection, and complex federal and state healthcare and privacy laws.
Castle Biosciences reported modest revenue growth for 2025 but a return to losses as reimbursement and amortization headwinds weighed on results. Full-year revenue was $344.2 million, up 4% from 2024, while total test reports for core dermatologic and GI drivers DecisionDx-Melanoma and TissueCypher grew 37%. TissueCypher volumes nearly doubled, rising to 39,014 tests from 20,956.
Despite strong volume, Medicare coverage changes for DecisionDx-SCC and discontinuation of IDgenetix limited top-line growth. Gross margin was 69% and Adjusted Gross Margin 80%, down from 79% and 82% in 2024, affected by lower DecisionDx-SCC revenue and a one-time $20.1 million amortization acceleration. Full-year net cash from operations was resilient at $64.3 million.
The company swung to a 2025 net loss of $24.2 million, versus net income of $18.2 million in 2024, with net loss per share of $0.83 and Adjusted Net Loss per Share of $0.14. Adjusted EBITDA declined to $44.0 million from $75.0 million. As of December 31, 2025, cash, cash equivalents and marketable securities totaled $299.5 million. Fourth-quarter revenue was $87.0 million, essentially flat year over year, with a quarterly net loss of $2.3 million. For 2026, Castle guides to total revenue of $340–350 million, implying roughly stable sales as it focuses on expanding adoption of its test portfolio, including the new AdvanceAD-Tx atopic dermatitis test.
Castle Biosciences, Inc. has a new large shareholder disclosure. RTW Investments, LP and its managing partner, Roderick Wong, M.D., report beneficial ownership of 2,115,237 shares of Castle Biosciences common stock, representing 7.2% of the company’s outstanding shares based on 29,188,659 shares outstanding as of October 27, 2025.
The shares are held by funds advised by RTW Investments, which have the right to receive dividends and sale proceeds. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Castle Biosciences.
Castle Biosciences president and CEO Derek J. Maetzold sold 4,017 shares of common stock in early February 2026 under a pre-arranged Rule 10b5-1 trading plan. Sales included 3,200 shares on February 3 at a weighted-average price of $39.913 and two sales on February 4 totaling 817 shares at weighted-average prices of $37.822 and $38.61. After these transactions, he directly held 83,698 common shares. He also reported indirect beneficial ownership of additional Castle Biosciences shares through multiple family and grantor retained annuity trusts.
Castle Biosciences Inc.’s President and Chief Executive Officer, Derek J. Maetzold, reported a planned sale of common stock under a pre-established Rule 10b5-1 trading plan. On January 20, 2026, he sold 4,017 shares of common stock at a weighted-average price of $40.013 per share in multiple trades within a disclosed price range.
Following this sale, Maetzold directly holds 87,715 shares of Castle Biosciences common stock, and additional shares are held indirectly through various family and grantor retained annuity trusts for which he or his spouse serves as trustee or beneficiary. The filing reflects an orderly, pre-planned diversification step rather than an ad hoc transaction.